Standard Biotools is trading 5.6% up at $0.69, with broader healthcare-sector gains on strong medical-device earnings supporting sentiment.
- No fresh company-specific announcement dated September 2, 2026 was identified in the available coverage.
- The latest material company news remains its August second-quarter report and ongoing Treeline Biosciences merger.